Categories: Manufacturers (D)

Arvind Remedies Ltd, 190, Poonamalle High Road, Chennai – 600 084, Tamilnadu, India

Company Name : Arvind Remedies Ltd

Address : 190, Poonamalle High Road, Chennai – 600 084, Tamilnadu, India

Tel No: 91-44-43439595, 26423265

Email : arl@arvindremedies.com, factory@arvindremedies.com

Website : http://www.arvindremedies.com/

Company Profile

Arvind Remedies Ltd forayed into the world of quality healthcare in 1988 under the dynamic and ambitious stewardship of Dr.Arvind Shah, Managing Director and CEO.

Incorporated as a Private Limited Company, we set out to manufacture and market world-class allopathic and ayurvedic pharmaceutical products within and outside India, thus beginning to realize the vision of bringing high quality healthcare to the common man. Since then, we have come a long way. Having grown notably in terms of production capacity, product categories, market share, advancements in R & D, market reach and global acceptance, we are today a significant force to reckon with in the Indian Pharmaceutical Industry.

We entered the field at a time when the Indian Pharmaceutical Industry was itself at the threshold of a new era, where product patenting and holistic healthcare were gaining prominence. Our core strength aptly lay in the ability to deliver both Western and Eastern varieties of quality treatments. Significant contributions have been made to the fields of Cardiology, Dermatology, Nephrology and Diabetes among others.

Having established our credibility as a company committed to providing world-class healthcare products, we went Public in April 1996 getting listed in Bombay Stock Exchange & National Stock Exchange in Mumbai, Ahmedabad and Chennai Stock Exchanges.

The Public Issue comprised of 30 Lakhs Equity Shares priced at Rs.10/- each at a premium of Rs.20/- per share.

In the year 1995 the company was converted to limited company.

In January 2001, the Company followed this up with a Rights Issue of 14.86 Lakhs Equity Shares of Rs.10/- each for cash at a premium of Rs.90/- per share.

We are a Profit-making, Dividend-paying Company with an Equity Share Capital of Rs.26 crores. In the Year 2002, each of the shares of Rs.10 were split into Rs.1 share and as on date there are 26, 00, 50, 000 fully paid shares.

In the Year 2002 the company issued bonus shares at the ratio of 5 shares for equal 2 shares held and 1857,50,000 equity shares were issued at Rs.1 Each

During the year 2010-11 the company has increased its authorized share capital to Rs.66 Crores and paid up capital for Rs.48.23 crores with the addition of preferential issue of 22.50 crores equity shares of Rs.1 each at premium of Rs.1.25 per share.

During the year 2012-13 company has started commercial operation of its new facility at irungatukottai,Kancheepuram Dt,Tamil nadu ,

which is plan for registration under USFDA

Arvind Remedies’ Indian client portfolio includes prestigious Defence Establishments, ESI, CGHS, Central and State Government

Institutions, Public Sector Companies, P&T, Railways and World Bank Projects. We have also won international acceptance

and recognition with our exports to Africa, Commonwealth of Independent States and Asian countries

The Pharma Times News Bureau

Recent Posts

World Diabetes Day Survey: Diabetologists and Endocrinologists demand for AI-Based Training and Upskilling in Diabetes Care

 A striking 90% of the 3000 Diabetologists and Endocrinologists surveyed, emphasised the importance of continuous…

3 days ago

Doctors warn diabetes patients about risk of smoking

People who smoke are also at much higher risk of developing diabetes compared to non-smokers…

5 days ago

CPHI & PMEC India Expo: Encouraging affordable solutions in India’s march towards a $130 Billion Pharma Market by 2030

17th edition of CPHI& PMEC India Expo to be held from 26th November-28thNovember 2024, at the India…

5 days ago

Sringeri Sharada Equitas Hospital Revolutionizing Cancer Care with the Launch of Low-cost, High Quality Radiation Therapy

The launch signifies Equitas’ redefined commitment to bring world-class cancer radiation therapy accessible to all.…

5 days ago